Cyclooxygenase-2 Genetic Variants Are Predictive of Patient Benefit: Biomarker Analyses from a Randomized Phase II Trial Evaluating Concurrent Chemoradiotherapy with or Without Celecoxib in Unresectable Stage III Non-Small Cell Lung Cancer | |
Bi, N.; Liang, J.; Zhou, Z.; Chen, D.; Fu, Z.; Yang, X.; Hui, Z.; Feng, Q.; Xiao, Z.; Lv, J. | |
2018 | |
卷号 | 102期号:3页码:S16-S17 |
ISSN号 | 0360-3016 |
DOI | 10.1016/j.ijrobp.2018.06.131 |
URL标识 | 查看原文 |
收录类别 | SCIE |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6351623 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Bi, N.,Liang, J.,Zhou, Z.,et al. Cyclooxygenase-2 Genetic Variants Are Predictive of Patient Benefit: Biomarker Analyses from a Randomized Phase II Trial Evaluating Concurrent Chemoradiotherapy with or Without Celecoxib in Unresectable Stage III Non-Small Cell Lung Cancer[J],2018,102(3):S16-S17. |
APA | Bi, N..,Liang, J..,Zhou, Z..,Chen, D..,Fu, Z..,...&Wang, L..(2018).Cyclooxygenase-2 Genetic Variants Are Predictive of Patient Benefit: Biomarker Analyses from a Randomized Phase II Trial Evaluating Concurrent Chemoradiotherapy with or Without Celecoxib in Unresectable Stage III Non-Small Cell Lung Cancer.,102(3),S16-S17. |
MLA | Bi, N.,et al."Cyclooxygenase-2 Genetic Variants Are Predictive of Patient Benefit: Biomarker Analyses from a Randomized Phase II Trial Evaluating Concurrent Chemoradiotherapy with or Without Celecoxib in Unresectable Stage III Non-Small Cell Lung Cancer".102.3(2018):S16-S17. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论